Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
Year: 2020
Type: conference-abstract
Source: Blood
Institutions: The University of Texas MD Anderson Cancer Center, Kite (United States), Banner MD Anderson Cancer Center, Hackensack University Medical Center, Moffitt Cancer Center, University of Rochester Medicine, Dana-Farber Cancer Institute, Cleveland Clinic, Texas Oncology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3097582500